Hims & Hers Health shares drop almost 4% after volatile open and downside gap

Traders Union
All News
Stocks
Hims & hers slides 3.83% today

Highlights

Hims & Hers Health reported second-quarter revenue of $753.2 million, a 38.2% increase year-over-year.
The company added 307,000 new customers to reach a total of 2.89 million and entered a strategic partnership with Novo Nordisk.
Shares of Hims & Hers Health are under near-term selling pressure but are projected to trade between $29.02 and $32.79 over the next five days, with a high probability of an upward move if $30.49 is reclaimed.

Customer surge and new partnership overshadowed by persistent selling

Hims & Hers Health reported second-quarter revenues of $753.2 million, reflecting a 38.2% increase year-over-year. The company added 307,000 new customers, bringing its total customer base to 2.89 million. An updated financial outlook was issued and a strategic partnership was entered into with Novo Nordisk. These developments occurred recently, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Hims & Hers Health is under persistent seller pressure despite strong revenue growth and a new partnership. He highlights the vulnerability in technicals with the price still below its short- and medium-term averages. Bearish momentum persists and recent gains in customer numbers are being overshadowed by negative short-term sentiment. Risk grows if the $29.02 level fails, with no clear reversal yet in sight. "I see the recent news as insufficient to overcome downside bias, and would advise caution until a convincing break above $30.49 occurs."

Viktoras Karapetjanc, expert at Traders Union, sees robust Q2 revenue growth and a major customer expansion as strong fundamental drivers for Hims & Hers Health. He points to the Novo Nordisk partnership as a critical step that broadens market opportunity and boosts brand confidence. Recent volatility does not disrupt the underlying bullish structure given healthy long-term support. He expects further growth if resistance at $30.49 is cleared decisively. "With the strategic backdrop strengthening, I believe the stock offers multiple setups for upside in the coming days."

Jainam Mehta, market strategist, observes mixed momentum as HIMS trades above its 200-day average but below short-term moving averages. He sees neutral indicators but spots a possible contrarian long if the price reclaims $30.49. Close monitoring of $29.02 as downside risk is warranted. "Potential breakout scenarios may emerge soon, so I would watch for tactical entries on a shift in short-term momentum."

Near-term resistance and buyer signals emerge amid ongoing volatility

Hims & Hers Health is trading below both its 20-day and 50-day moving averages ($30.49 and $32.17, respectively), signaling seller-driven pressure in the near and medium term. It remains above the long-term 200-day average at $28.67, which offers key support. The near-term resistance is at $30.49 (MA-20), with support at $30.05 (Ichimoku Kijun). RSI is neutral at 52.12 but issues a buy signal, while Stochastic RSI indicates emerging upside momentum. MACD and ADX both show neutral readings, and Bull/Bear Power at 1.19 points to buyer dominance, although the overbought label warrants caution. Recent trading saw a $1.21 drop amid heightened volatility, confirming that sellers are dictating direction for now, even as certain momentum signals remain mixed to bullish.

Earlier, analysts noted that Hims & Hers Health’s strong revenue growth and improved guidance had set a constructive medium-term outlook. The current pattern of short-term technical weakness despite positive fundamentals adds a layer of caution for traders, who should monitor $30.49 as a pivotal level for any potential upside reversal.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.